Pfizer's groundbreaking HYMPAVZI has received FDA approval for routine prophylaxis in hemophilia A or B without inhibitors, offering a convenient subcutaneous treatment with once-weekly dosing.
Revolutionizing Treatment
The approval of HYMPAVZI marks a milestone in hemophilia care, being the first anti-TFPI treatment approved in the U.S. and the inaugural therapy administered via a pre-filled auto-injector pen, designed to alleviate treatment burden.
Advancing Bleeding Management
The introduction of HYMPAVZI represents a significant step forward in managing bleeding episodes in hemophilia, boasting a manageable safety profile and a simple administration process.
Clinical Efficacy
Results from the Phase 3 BASIS trial displayed a remarkable 35% reduction in the annualized bleeding rate for treated bleeds with HYMPAVZI, along with a consistent safety profile. The most common adverse reactions reported were injection site reactions, headache, and pruritus.
Commitment to Hemophilia Patients
HYMPAVZI is just one facet of Pfizer's dedication to enhancing care for individuals with hemophilia. The company's overarching goal is to address the diverse treatment needs of hemophilia patients through a range of medications, including gene therapy and recombinant factor treatments.
Driving Progress
Pfizer's approval of HYMPAVZI signals a new era in hemophilia treatment, offering patients a more convenient and effective option to manage their condition. With a focus on innovation and patient-centric care, Pfizer continues to lead the way in advancing healthcare for individuals with hemophilia.